VERIGRAFT AB today announce a committed capital contribution of SEK 110 million from an existing long-term shareholder. This investment strengthens VERIGRAFT’s balance sheet and extends the company’s financial flexibility as it prepares for the next phase of its clinical program, including Phase II/III (pivotal) trial readiness in both Europe and the United States.
Strategic rationale
The capital contribution reflects confidence in VERIGRAFT’s strategy, execution, and long-term value potential. The shareholder – an established owner with biotech expertise, and with deep insight into VERIGRAFT’s development plan – is increasing its commitment during this strategic timeframe as the company approaches multiple value-creating milestones and accelerates preparations for the next clinical stage.
Use of fund
Advancing pivotal execution readiness the proceeds will support the company’s transition into its next clinical phase, with a focus on enabling Phase II/III (pivotal) execution and key enabling activities.
Planned priorities include:
- Pivotal trial preparation and initiation in Europe and the US
- Regulatory and submission-related activities
- Manufacturing and CMC readiness
- Clinical infrastructure and program execution capabilities
- Working capital and general corporate purposes
Enhanced runway and milestone focus
With a strengthened financial position, VERIGRAFT can maintain momentum, improve capital efficiency, and progress toward near-term execution milestones linked to initiating the next clinical phase in Europe and the Unites States.
“This investment represents strong long-term conviction from a shareholder who knows VERIGRAFT and our development plan well,” said Petter Björquist, CEO of VERIGRAFT. “It enhances our financial flexibility and supports our preparations for a Phase II/III pivotal program across Europe and the US. We believe this funding positions us well to execute the next clinical steps with focus, speed, and discipline as we approach important value-creating milestones.”
About VERIGRAFT
VERIGRAFT continues to advance its technology with the ambition to redefine transplant medicine through personalized tissue therapies. Moreover, the reinforced ownership support and improved financial flexibility strengthen VERIGRAFT’s ability to execute its strategy and deliver long-term value creation.